BridgeMD
New treatment option for Cytomegalovirus Retinitis
Official title Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
ClinicalTrials.gov ID: NCT05911503
What this study is testing
What is 2% Ganciclovir Eye Drops?
2% Ganciclovir Eye Drops is an investigational medicine, being studied as a potential treatment for cytomegalovirus retinitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 80
You may be able to join if
- Patients voluntarily participate in studies and sign informed consent forms
- Ages 2-80 years (with cut-off values) male and female
- One of the following is true （1）In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation/cord blood transplantation...
You likely can't join if
- Eye condition
- The presence of refractive interstitial opacification affects fundus observation;
- Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline;
- Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal...
- General condition
- Severe neutropenia (\<0.5×10\^9) or severe thrombocytopenia (\< 25× 10\^9/L);
See the full eligibility criteria
- Patients voluntarily participate in studies and sign informed consent forms
- Ages 2-80 years (with cut-off values) male and female
- One of the following is true （1）In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation/cord blood transplantation, the white blood cell count is less than 4× 10\^9/L, and the platelet...
- Eye condition
- The presence of refractive interstitial opacification affects fundus observation;
- Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline;
- Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal lesions, congenital macular degeneration, etc.
- General condition
- Severe neutropenia (\<0.5×10\^9) or severe thrombocytopenia (\< 25× 10\^9/L);
- Other investigators judged patients who were not suitable for enrollment;
The study team makes the final eligibility decision.
Where it's taking place
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.